IMAB I-MAB ADS (N Shares)

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025.

Details are as follows:

24th Annual Needham Virtual Healthcare Conference 
Conference Date:April 7-10, 2025
Format:Company Presentation and one-on-one meetings
Presentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ET
Webcast Link:Register
  

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: and follow us on and .

I-Mab Investor & Media Contacts

PJ Kelleher

LifeSci Advisors







EN
26/03/2025

Underlying

IMABI-MAB ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on I-MAB ADS (N Shares)

 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD,...

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a physician-entrepreneur and founder with a proven track record in business development, Dr. Cunningham aims to bolster NovaBridge’s mission to accelerate access to transformative medicinesDr. Cunningham, co-founder of NovaBridge su...

February 19, 2026 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of ...

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line (1L) metastatic gastric cancerMajor milestone builds on positive Phase 1b combination data demonstrating that givastomig produced, best-in-class potential efficacy in 1L HER2-negative, metastatic gastric cancer patients in combination ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu W...

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei Executive Chairman of the Board, Fu Wei, informed the Company of his intent to purchase up to $5,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to $5,000,000 of the Company’s ADSs in open market transactions. T...

January 20, 2026 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Presents Positive Givastomig Dose Expansion Data from the P...

NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg, across a wide range of PD-L1 and CLDN18.2 expression levelsThe median PFS was 16.9 months at 8 mg/kg; 12 mg/kg is immature with approximately 4-month shorter median follow-up; data will be...

January 6, 2026 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026

NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening the first trading session of the New Year marks an excellent beginning to 2026 for NovaBridgeInclusion in the Nasdaq Biotech Index (NBI) enhances NovaBridge’s visibility and emphasizes the Company’s position as an industry leader ROCKVILLE, Md., Dec. 30, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to ...

December 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch